NeurAxis, Inc. Hits New 52-Week High of $6.35, Up 98.97%

NeurAxis, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 6.35 on March 4, 2026. This achievement marks a remarkable increase of 98.97% over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.36% during the same period. With a market capitalization of USD 59 million, NeurAxis operates in a competitive industry characterized by innovation and rapid advancements. The company's financial metrics reflect its current standing, with a price-to-book ratio of 25.78. However, it is important to note that NeurAxis is currently loss-making, as indicated by its negative P/E ratio and a return on equity of -330.30%. Additionally, the company does not offer a dividend, and its debt-to-equity ratio stands at -1.80. The achievement of this new high underscores NeurAxis's notable performance in the market, highlighting its potential within the dynamic landscape of pharmaceuticals and biotechnology.